Hara, Chikako
Kamei, Motohiro http://orcid.org/0000-0001-7666-6456
Sakaguchi, Hirokazu
Matsumura, Nagakazu
Sakimoto, Susumu
Suzuki, Mihoko
Nishida, Kentaro
Fukushima, Yoko
Nishida, Kohji
Funding for this research was provided by:
the Ministry of Education, Science and Culture of Japan (a Grant-in-Aid for Scientific Research 15K10893)
Article History
Received: 12 August 2020
Revised: 14 December 2020
Accepted: 5 January 2021
First Online: 24 April 2021
Compliance with ethical standards
:
: None of the authors has a proprietary interest or conflict of interest in any product mentioned in this article. Dr. Hara affiliate Endowed department (Menicon) has received lecture fees from Alcon Pharma, Bayer, Santen, Pfizer, and Senju. Dr. Kamei has received grants and lecture fees from HOYA, AMO, Pfizer, Novartis (Alcon Pharma), Kowa, Santen, Senju, Ootsuka, RE Medical, Alcon, Bayer and NIDECK, grants from Handaya, Ellex, and Bausch & Lomb, and consulting fee from Astellas and Senju. Dr. Sakaguchi affiliate Endowed department (Menicon) and has lecture fees from Alcon Pharma, lecture fees from Nihon Alcon, personal fees from Santen, outside the submitted work. Dr. Kohji Nishida has received lecture fees from Alcon, Carl Zeiss, Otsuka, Pfizer, Santen, and Senju, and grants from HOYA and Santen. Dr. Matsumura, Dr. Kentaro Nishida, Dr. Suzuki Dr. Sakimoto and Dr. Fukushima have no disclosures.
: The Institutional Review Board approved the study protocol and the procedures conformed to the tenets of the World Medical Association’s Declaration of Helsinki. Ten eyes of nine patients who had completed the previous 1-year prospective pilot study (UMIN000008976) were included.
: All patients provided informed consent after they received an adequate explanation of the procedures to be performed.
: The code during and/or analyzed during the current study are available from the corresponding author on reasonable request.